Parambir Dulai
Gastroenterology · Chicago, ILNPI 1811214364
Payments from drug & device makers
Across 474 payments — averaging $4618.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1.2M
- Janssen Scientific Affairs, LLC$348K
- Pfizer$183K
- AbbVie$173K
- Johnson & Johnson$108K
- Janssen Research & Development, LLC$91K
- plus $126K from 16 others
Across 6 payments — averaging $358.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 115 | $1,161,318 |
| Janssen Scientific Affairs, LLC | 33 | $348,023 |
| Pfizer | 10 | $182,545 |
| AbbVie | 122 | $172,533 |
| Johnson & Johnson | 75 | $107,563 |
| Janssen Research & Development, LLC | 20 | $90,765 |
| Janssen Global Services, LLC | 29 | $30,275 |
| E.r. Squibb & Sons, L.L.C. | 22 | $24,784 |
| Genentech, Inc. | 11 | $22,540 |
| Sanofi | 6 | $16,995 |
| Takeda | 4 | $13,901 |
| Boehringer Ingelheim | 1 | $5,300 |
| Celltrion USA Inc. | 2 | $2,465 |
| Lilly USA, LLC | 1 | $2,400 |
| Genentech USA, Inc. | 5 | $2,283 |
| Gilead | 1 | $2,030 |
| Eli Lilly | 1 | $1,600 |
| Bristol Myers Squibb | 11 | $1,455 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $88 |
| Boston Scientific | 1 | $71 |
| Baxter Healthcare | 2 | $38 |
| Mauna Kea Technologies, Inc. | 1 | $37 |
How this compares
$2,189,009 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Chicago
- David RubinChicago$3.6M
- Stephen HanauerChicago$2.9M
- Ikuo HiranoChicago$1.8M
- Steven FlammChicago$1.6M
- Darren BrennerChicago$1.1M
- Russell CohenChicago$985K
- Mary RinellaChicago$938K
- Emanuelle BellaguardaChicago$868K
- Saurabh KapurChicago$867K
- Benjamin LevyChicago$759K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.